Capital Research & Management Co recently announced the acquisition of new stake in Grifols SA ADR (NASDAQ:GRFS). The institutional investor has increased its shareholding in the Healthcare company by 0.58% to 19.63 million shares with purchase of 0.11 million shares. This fresh investment now brings its stake to 7.51% valued currently at $226.91 million. In addition, Brandes Investment Partners LP raised its holdings by 0.84 million to 11.06 million shares. And Black Creek Investment Management has lifted its position by 16.43% or 1.35 million shares – to 9.57 million shares.
Currently, there are 256.23M common shares owned by the public and among those 255.74M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The top 3 mutual fund holders in Grifols SA ADR are American Funds New Perspective Fu, First Trust NYSE Arca Biotechnolo, and American Funds International Grow. American Funds New Perspective Fu owns 13.38 million shares of the company’s stock, all valued at over $154.68 million. First Trust NYSE Arca Biotechnolo sold 28612.0 shares to see its total holdings shrink to 4.64 million shares valued at over $53.58 million and representing 1.77% of the shares outstanding. American Funds International Grow sold 1378.0 shares to bring its total holdings to over 4.0 million shares at a value of $46.21 million. American Funds International Grow now owns shares totaling to 1.53% of the shares outstanding.
However, the script later moved the day high at 6.95, up 0.15%. The company’s stock has a 5-day price change of -15.08% and -20.94% over the past three months. GRFS shares are trading -41.52% year to date (YTD), with the 12-month market performance down to -26.60% lower. It has a 12-month low price of $6.35 and touched a high of $12.15 over the same period. GRFS has an average intraday trading volume of 1.98 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -30.37%, -30.37%, and -25.86% respectively.
Institutional ownership of Grifols SA ADR (NASDAQ: GRFS) shares accounts for 47.53% of the company’s 256.23M shares outstanding. Mutual fund holders own 19.94%, while other institutional holders and individual stakeholders account for 26.87% and — respectively.
It has a market capitalization of $1.73B and a beta (3y monthly) value of 0.62. The stock’s trailing 12-month PE ratio is 965.71, while the earnings-per-share (ttm) stands at $0.01. The company has a PEG of 29.81 and a Quick Ratio of 0.79 with the debt-to-equity ratio at 1.71. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.76% over the week and 5.85% over the month.
Analysts forecast that Grifols SA ADR (GRFS) will achieve an EPS of $Grifols, S.A. for the current quarter, $6.76 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Gritstone bio, Inc. while analysts give the company a high EPS estimate of $BRF S.A.. Comparatively, EPS for the current quarter was $Graphex Group Limited a year ago. Earnings per share for the fiscal year are expected to increase by 1.89%, and 112.86% over the next financial year. EPS should grow at an annualized rate of 32.40% over the next five years, compared to -21.67% over the past 5-year period.
